Replies to post #489 on Cynapsus Therapeutics Inc. (CYNA)

[Citrati]

I think you are giving reasonable perspective. I also agree that there is not time to dilly dally.
Thanks

One persons opinion below.

Jason Napodano, Zacks Investment Research (1/5/15)
"We continue to believe that Cynapsus Therapeutics Inc.'s stock represents an attractive opportunity for investors. We believe APL-130277 is a superior drug in design, safety and mechanism of action to CVT-301, a drug recently acquired by Acorda Therapeutics Inc. for $525M in cash; we estimate that Cynapsus is approximately two to four months behind Acorda in Phase 3 development of their respective drugs but would not be surprised to see Cynapsus pass Acorda when it comes to final approval."

CYNAF

[kris_kade]

I am not entirely dismissing either. However at minimum valuation of Cynapsus should match with Civitas buyout premium ($525 million). With around 80 million shares outstanding for Cynapsus (not including warrants), it should trade well north of $5 upon Phase 3 initiation.

Unless of course there is a buyout before then :-)